Cite
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
MLA
Landewé, Robert B. M., et al. “Maintenance of Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Dose Reduction.” Annals of the Rheumatic Diseases, vol. 79, no. 7, July 2020, pp. 920–28. EBSCOhost, https://doi.org/10.1136/annrheumdis-2019-216839.
APA
Landewé, R. B. M., van der Heijde, D., Dougados, M., Baraliakos, X., Van den Bosch, F. E., Gaffney, K., Bauer, L., Hoepken, B., Davies, O. R., de Peyrecave, N., Thomas, K., Gensler, L., & Landewé, R. B. (2020). Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction. Annals of the Rheumatic Diseases, 79(7), 920–928. https://doi.org/10.1136/annrheumdis-2019-216839
Chicago
Landewé, Robert B. M., Désirée van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip E. Van den Bosch, Karl Gaffney, Lars Bauer, et al. 2020. “Maintenance of Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Dose Reduction.” Annals of the Rheumatic Diseases 79 (7): 920–28. doi:10.1136/annrheumdis-2019-216839.